论文部分内容阅读
为进一步验证氯氮平在治疗精神分裂症中的地位。方法对病程＜５年的１２２例首次住院的精神分裂症患者，采用分层随机法分为两组，分别首选氯氮平和氯丙嗪进行８周治疗。以ＢＰＲＳ、ＳＡＰＳ、ＳＡＮＳ评定疗效，以ＴＥＳＳ评定副反应。结果治疗前后比较，两组ＢＰＲＳ、ＳＡＰＳ分均显著下降（Ｐ＜０．０１），ＳＡＮＳ分氯氮平组显著降低（Ｐ＜０．０１），氯丙嗪组无明显差异（Ｐ＞０．０５）；疗后氯氮平组的ＢＰＲＳ、ＳＡＰＳ、ＳＡＮＳ总分均明显低于氯丙嗪组（Ｐ＜０．０１）；ＴＥＳＳ总分氯氮平组亦低于氯丙嗪组，且无锥体外系副反应。结论氯氮平确是一种十分有效且药物副反应并不多见的抗精神病药。在严密监测血象的情况下，氯氮平实际上可作为一个可供选择的治疗精神分裂症的第一线药使用。
To further validate clozapine in the treatment of schizophrenia status. Methods A total of 122 first-episode schizophrenia patients with a history of less than 5 years were divided into two groups according to a stratified randomized trial. Clozapine and chlorpromazine were the first choice for 8 weeks. The efficacy was evaluated by BPRS, SAPS and SANS, and the side effects were evaluated by TESS. Results Before and after treatment, the BPRS and SAPS scores in both groups decreased significantly (P <0.01), SANS decreased significantly in clozapine group (P <0.01) and no significant difference was found in chlorpromazine group (P> 0.05). 05). After treatment, the scores of BPRS, SAPS and SANS in clozapine group were significantly lower than those in chlorpromazine group (P <0.01). The TESS total clozapine group was also lower than that of chlorpromazine group Extrapyramidal side effects. Conclusions Clozapine is indeed a very effective antipsychotic drug with few side effects. Clozapine can actually be used as a first line of treatment for schizophrenia when it is closely monitored.